Stanford gene-editing startup raises $150M for sickle cell clinical trial, expansion into rare diseases

The South San Francisco company's early work at Stanford — as well as the work of a critical partner — was backed by grants from California's stem cell research funding agency CIRM.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news